A part of Watch Media

MedWatchWednesday4 October 2023

  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
MedWatchWednesday4 October 2023
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
MedWatch.com

Blackstone is using AI to control diabetes and slash spending on drugs

Using an AI-based approach, US-based alternatives asset manager seeks to cut costs and improve workers’ health without relying on expensive new drugs from drugmakers like Novo Nordisk and Eli Lilly. 
Photo: Jeenah Moon/Reuters/Ritzau Scanpix
Photo: Jeenah Moon/Reuters/Ritzau Scanpix
By John Tozzi, bloomberg

Blackstone Inc. is trying to curb rising employee health costs with an AI-powered individualized approach to diabetes to reduce people’s reliance on costly new drugs. Early results are promising.

The private equity giant is testing a program from startup Twin Health with workers across 14 of its portfolio companies. The app is designed to help diabetics rely less on expensive drugs to lose weight and control their blood sugar. Patients with uncontrolled diabetes often move from older, lower-priced drugs onto newer pricey treatments made by Novo Nordisk A/S and Eli Lilly & Co. that can cost around USD 10,000 a year.

To help do this, Twin Health uses artificial intelligence and machine learning to analyze data from glucose monitors, activity trackers and surveys. The result is instant, personalized advice for diet, exercise and other activities that takes into account how users are feeling, what they’ve eaten or where they are. If users are able to get their blood sugar under control with these behavior changes, they can feasibly avoid higher-priced drugs.

Medication costs fell by half for 160 people enrolled at least three months in the program, including a roughly 90% drop in spending on drugs like Novo’s Ozempic, Blackstone said. After two months, people in the program lost an average of 12 pounds.

Growing market

Drugs like Ozempic are being repurposed for weight loss and are expected to cost the medical system billions of dollars if they’re widely prescribed for weight management. Morgan Stanley Research analysts estimate spending on obesity drugs could reach USD 54bn by 2030.

As diabetes treatments, these same drugs — Ozempic and Lilly’s Trulicity and Mounjaro — are already pushing up costs for employers like Blackstone. These medications control blood sugar and come with the long sought after benefit of reducing patients’ body weight.

Blackstone is testing the Twin Health app with just 14 of its companies and estimates they will save hundreds of thousands of dollars a year in drug costs for the people signed up so far. If more workers join, savings could be far greater across its portfolio of 122 businesses.

“We’ve never thrown the full weight of our entire team behind an effort like this,” said Andreas Mang, chief executive officer of Blackstone’s Equity Healthcare division, which works with portfolio companies to improve health benefits. Blackstone has no financial interest in Twin Health.

Type 2 diabetes, the most common form of the illness, occurs when the body doesn’t respond properly to insulin, often leading to chronic high blood sugar levels that are linked to heart, kidney and eye complications. Affecting about 1 in 10 Americans, it’s among the top drivers of US health spending with costs of more than USD 300bn a year.

”Micro actions”

For years employers have been experimenting with programs from companies like Livongo Health Inc., Omada Health Inc. and Virta Health Corp. aimed at promoting lifestyle changes to improve health outcomes. While some interventions have had promising results, few have been shown to improve patients’ health over the long term.

The problem is that most add-ons to employer health plans struggle to get people engaged, Mang said. Twin Health’s app recommends “micro actions, little things that people can do in their daily routine that are very specific to them, that day, that moment,” said Lisa Shah, Twin Health’s chief medical officer. “If you’re on an eight-hour plane ride, you’re not going to be taking 10,000 steps that day,” she said. The app will prompt people to stand up periodically and adjust other recommendations for food and activity the next day to compensate.

Twin Health users get health coaching and supervision from clinicians with the goal of getting people to control their blood sugar without drugs. It can be done, said Anne Peters, a professor of clinical medicine at University of Southern California – the hard part is making it stick.

“Almost every single program shows that you can make people better for six months,” says Peters, who has consulted for companies on diabetes programs but not for Twin Health. “The question is, how do you make it persist for years and years?”

Blackstone believes Twin Health is different, partly because it only gets paid if it shows results like helping people lower their blood sugar.

The firm started rolling out the program last June. About 15% of the target population at those companies signed up — better adoption rates than employer-sponsored health programs typically see, Mang said. Workers don’t get financial incentives to join.

Diabetes is one of the top three most expensive conditions each year at Blackstone portfolio company Medline Industries. More than a third of the roughly 90 people at the company who have been on the Twin Health program for at least two months have been able to go off high-cost diabetes medications, said Lori Buckley, Medline’s vice president of HR for benefits. She said some employees have called the program “life changing.” 

Founded in Mountain View, California, in 2018, Twin Health has dozens of other employer clients and and recently signed up Berkshire Hathaway-owned insurer Geico.

Share article

Related articles:

  • Photo: Dorthe Bach

    Novo Nordisk's crazy growth impresses analyst: "My estimates have been exceeded"

    For subscribers

  • Photo: Brendan Mcdermid/Reuters/Ritzau Scanpix

    WeightWatchers enters weight loss drug market with acquisition

    For subscribers

  • Photo: Mike Blake

    Eli Lilly's Mounjaro could overtake Wegovy, says professor

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Foto: Tom Little
Pharma & biotech

Investment bank: Novo Nordisk's patent victory is a small victory as price negotiations loom

The market’s attention is more focused on public health insurance Medicare’s new price negotiations under the so-called Inflation Reduction Act.
  • Bank downplays importance of patent dispute and FDA notice to Novo Nordisk
  • Jefferies on Novo Nordisk: Little risk of semaglutide patent dispute - but could raise concerns

For subscribers



Foto: Tom Little
Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

For subscribers



Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Foto: Liselotte Plenov / Fotorummet / Pr
Pharma & biotech

Fujifilm expands management with former Leo executive

For subscribers


Foto: Andrew Kelly/Reuters/Ritzau Scanpix
Pharma & biotech

Low share price may knock Galecto off the stock exchange

For subscribers


Foto: Mike Segar/Reuters/Ritzau Scanpix
Pharma & biotech

Snack maker keeps an eye on Novo Nordisk's obesity drug


Foto: Yuriko Nakao/Reuters/Ritzau Scanpix
Medtech

Olympus appoints new chief medical officer

For subscribers


  • Foto: Alexander Heinl/AP/Ritzau Scanpix

    Novo Nordisk's semaglutide to be studied for positive effect on alcoholics

    Previous studies have shown that alcohol cravings disappeared when people were treated with GLP-1 agonist exanatide.

    For subscribers


  • Vaccine breakthrough behind mRNA shots wins Nobel Prize

    The two scientists will share the 11 million-krona ( USD 1 million) award, the Nobel Assembly at the Karolinska Institutet in Stockholm said in a statement Monday.

    For subscribers


  • Foto: Ws Audiology / Pr

    WS Audiology hires new chief technology officer from car manufacturer

    He succeeds chief research & development officer Stefan Menzl, who is stepping down after six years.

    For subscribers


  • Foto: Tom Little

    Novo Nordisk files lawsuit against US authorities ahead of price negotiation

    The litigation is the latest in a long line of industry lawsuits related to price negotiations.

    For subscribers


  • Foto: Mike Segar

    FDA rejects atopic dermatitis drug lebrikizumab

    Eli Lilly had expected a launch this year.

    For subscribers


  • The FDA has updated the package label of Novo Nordisk's diabetes drug, Ozempic, with a warning about intestinal blockage disorder as a possible side effect. | Foto: Tom Little/Reuters/Ritzau Scanpix

    FDA updates Novo Nordisk's Ozempic drug label with side effect alert

    The diabetes drug might cause a potentially fatal intestinal blockage, the authorities warn.

    For subscribers


Further reading

Foto: Tom Little
Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

For subscribers



Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Foto: Liselotte Plenov / Fotorummet / Pr
Pharma & biotech

Fujifilm expands management with former Leo executive

The contract manufacturer has hired a chief people officer with immediate effect.

For subscribers



Foto: Mike Segar/Reuters/Ritzau Scanpix
Pharma & biotech

Snack maker keeps an eye on Novo Nordisk's obesity drug

”As with anything that could potentially impact our business, we’re looking at it,” says the former Kellogg’s CEO.

Foto: Alexander Heinl/AP/Ritzau Scanpix
Pharma & biotech

Novo Nordisk's semaglutide to be studied for positive effect on alcoholics

Previous studies have shown that alcohol cravings disappeared when people were treated with GLP-1 agonist exanatide.

For subscribers



Genmab CEO Jan van de Winkel and director general of The Confederation of Danish Industry, Lars Sandahl Sørensen. | Photo: Genmab / PR
Pharma & biotech

Genmab has officially opened its new headquarters

The CEO describes the new premises as a symbol of the company’s commitment to advancing science and innovation.

For subscribers



Foto: Yuriko Nakao/Reuters/Ritzau Scanpix
Medtech

Olympus appoints new chief medical officer

The new medical director is brought in from Medtronic. 

For subscribers


Jobs

  • Global Medical Manager

  • Senior CMC Specialist, Upstream Processing, Genmab

  • Audit & Supplier Manager

  • Clinical Trial Manager

  • Senior Analytical Scientists

  • QA/RA Manager

  • VP of Software Development, Perfusion Tech

  • Scientist - Bioanalysis, Biologics

  • Project Director, HR & ESG

  • Senior Legal Councel

  • Director, Head of Antibody Technology

  • Supply Value Stream (SVS) Project Manager

  • Clinical Supply Manager

  • Senior QA Specialists (GMP or GCP)

  • Qualified Person to AJ Vaccines

See all jobs

Latest news

  • Investment bank: Novo Nordisk's patent victory is a small victory as price negotiations loom –
  • Novo Nordisk's semaglutide to be studied for positive effect on alcoholics –
  • Olympus appoints new chief medical officer –
  • Low share price may knock Galecto off the stock exchange –
  • Fujifilm expands management with former Leo executive –
  • Snack maker keeps an eye on Novo Nordisk's obesity drug –
  • FDA approves Novo Nordisk drug to treat rare condition –
  • FDA updates Novo Nordisk's Ozempic drug label with side effect alert –
  • FDA rejects atopic dermatitis drug lebrikizumab –
  • FDA to support new orphan drugs through pilot program –
See all

Jobs

  • Global Medical Manager

  • Senior CMC Specialist, Upstream Processing, Genmab

  • Audit & Supplier Manager

  • Clinical Trial Manager

  • Senior Analytical Scientists

  • QA/RA Manager

  • VP of Software Development, Perfusion Tech

  • Scientist - Bioanalysis, Biologics

  • Project Director, HR & ESG

  • Senior Legal Councel

  • Director, Head of Antibody Technology

  • Supply Value Stream (SVS) Project Manager

  • Clinical Supply Manager

  • Senior QA Specialists (GMP or GCP)

  • Qualified Person to AJ Vaccines

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

  • About MedWatch

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Banner Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved